Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
622
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Behcet’s-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review

Kecen Liua Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China;b Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China;c National Clinical Research Center for Skin and Immune Diseases, Beijing, China;d NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, ChinaORCID Iconhttps://orcid.org/0009-0001-5846-7776View further author information
ORCID Icon &
Jingru Suna Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China;b Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China;c National Clinical Research Center for Skin and Immune Diseases, Beijing, China;d NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2507-5220View further author information
ORCID Icon
Article: 2347440 | Received 13 Mar 2024, Accepted 14 Apr 2024, Published online: 10 Jun 2024

References

  • Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical ­eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1–6. doi: 10.1016/j.jaad.2020.12.010.
  • Shiga H, Fukuda S, Iijima K. Interleukin-17A inhibitor-induced Crohn’s disease/Behcet’s disease-like lesions. Inflamm Bowel Dis. 2017;23(6):E38–E39. doi: 10.1097/MIB.0000000000001142.
  • Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced Behcet’s syndrome: a report of two cases. Oxf Med Case Reports. 2019;2019(5):omz041. doi: 10.1093/omcr/omz041.
  • Barrado-Solís N, Rodrigo-Nicolás B, De la Morena-Barrio I, et al. Report of two cases of Behcet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol. 2020;34(10):e587–e589. doi: 10.1111/jdv.16454.
  • Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ, et al. Behcet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges. 2021;19(1):116–118. doi: 10.1111/ddg.14196.
  • Chen D, Zhou M, Xu A, et al. Behcet’s-like disease in a patient treated with ixekizumab for chronic plaque psoriasis. Scand J Rheumatol. 2022;51(4):336–337. doi: 10.1080/03009742.2021.2014105.
  • Avcı C, Akın G, Akarsu S, et al. Pyoderma gangrenosum and Behcet’s-like disease induced by secukinumab: a paradoxical drug reaction. J Dermatolog Treat. 2023;34(1):2235040. doi: 10.1080/09546634.2023.2235040.
  • Ogasawara M, Taniguchi Y. IL-17 inhibitor-induced Behcet-Like disease. J Clin Rheumatol. 2023;30(2):e65. doi: 10.1097/RHU.0000000000002025.
  • Sun FSK, Chiu NSY, Chung HY. Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy. BMC Rheumatol. 2023;7(1):25. doi: 10.1186/s41927-023-00344-9.
  • van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet’s disease and treatment ­modalities. Semin Arthritis Rheum. 2022;52:151956. doi: 10.1016/j.semarthrit.2022.151956.
  • Takeno M. The association of Behçet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34(1):4–9. doi: 10.1097/bor.0000000000000846.
  • Bodis G, Toth V, Schwarting A. Role of human leukocyte ­antigens (HLA) in autoimmune diseases. Rheumatol Ther. 2018;5(1):5–20. doi: 10.1007/s40744-018-0100-z.
  • Di Scala G, Bettiol A, Cojan RD, et al. Efficacy of the anti-IL 17 secukinumab in refractory Behcet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108–113. doi: 10.1016/j.jaut.2018.09.002.
  • Joubert M, André M, Barnich N, et al. Microbiome and Behçet’s disease: a systematic review. Clin Exp Rheumatol. 2023;41(10):2093–2104. doi: 10.55563/clinexprheumatol/zbt4gx.
  • Huang YH, Chang LC, Chang YC, et al. Compositional ­alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors. Int J Mol Sci. 2023;24(5):4568. doi: 10.3390/ijms24054568.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.